Esophageal Hypervigilance and Symptom-Specific Anxiety in Patients with Eosinophilic Esophagitis.
Adolescent
Adult
Aged
Anxiety
/ diagnosis
Cost of Illness
Deglutition
Diet
/ adverse effects
Endoscopy, Gastrointestinal
Eosinophilic Esophagitis
/ diagnosis
Female
Health Status
Humans
Male
Middle Aged
Predictive Value of Tests
Quality of Life
Registries
Retrospective Studies
Self Report
Symptom Assessment
Young Adult
Eosinophilic Esophagitis
Hypervigilance
Quality of Life
Symptom Severity
Symptom-Specific Anxiety
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
22
04
2021
revised:
01
06
2021
accepted:
11
06
2021
pubmed:
22
6
2021
medline:
18
1
2022
entrez:
21
6
2021
Statut:
ppublish
Résumé
Patient symptom reporting often does not correlate with the pathophysiological markers of esophageal disease, including eosinophilic esophagitis (EoE). Esophageal hypervigilance and symptom-specific anxiety are emerging as important considerations in understanding symptom reporting. As such, we aimed to conduct the first study of these constructs in EoE. A retrospective review of an EoE patient registry was conducted and included eosinophils per high power field (from esophagogastroduodenoscopy biopsy: proximal, distal), endoscopic reference score, distal distensibility plateau (functional luminal imaging probe), Brief Esophageal Dysphagia Questionnaire, Visual Dysphagia Question of EoE Activity Index, Northwestern Esophageal Quality of Life scale, and the Esophageal Hypervigilance and Anxiety Scale. Correlational and regression analyses evaluated relationships of hypervigilance and anxiety with Brief Esophageal Dysphagia Questionnaire, Visual Dysphagia Question of EoE Activity Index, and Northwestern Esophageal Quality of Life scale when controlling for histology and endoscopic severity. One hundred and three patients had complete data, 69.9% were male, and the mean (SD) age was 40.66 (13.85) years. Forty-one percent had elevated dysphagia and 46% had elevated hypervigilance and anxiety. Esophageal symptom-specific anxiety emerged as the most important predictor of Brief Esophageal Dysphagia Questionnaire severity (44.8% of the variance), Visual Dysphagia Question of EoE Activity Index severity (26%), and poor health-related quality of life (HRQoL) (55.3%). Hypervigilance was also important, but to a lesser extent. Pathophysiological variables did not significantly predict symptoms or HRQoL. Recent food impaction can predict symptom-specific anxiety and proton pump inhibitor use can reduce hypervigilance. Hypervigilance and symptom-specific anxiety are important for our understanding of self-reported patient outcomes in EoE. These processes outweigh endoscopic and histologic markers of EoE disease activity across dysphagia, difficulty eating, and HRQoL. Clinicians should assess hypervigilance and anxiety, especially in patients with refractory symptoms and poor HRQoL.
Sections du résumé
BACKGROUND & AIMS
Patient symptom reporting often does not correlate with the pathophysiological markers of esophageal disease, including eosinophilic esophagitis (EoE). Esophageal hypervigilance and symptom-specific anxiety are emerging as important considerations in understanding symptom reporting. As such, we aimed to conduct the first study of these constructs in EoE.
METHODS
A retrospective review of an EoE patient registry was conducted and included eosinophils per high power field (from esophagogastroduodenoscopy biopsy: proximal, distal), endoscopic reference score, distal distensibility plateau (functional luminal imaging probe), Brief Esophageal Dysphagia Questionnaire, Visual Dysphagia Question of EoE Activity Index, Northwestern Esophageal Quality of Life scale, and the Esophageal Hypervigilance and Anxiety Scale. Correlational and regression analyses evaluated relationships of hypervigilance and anxiety with Brief Esophageal Dysphagia Questionnaire, Visual Dysphagia Question of EoE Activity Index, and Northwestern Esophageal Quality of Life scale when controlling for histology and endoscopic severity.
RESULTS
One hundred and three patients had complete data, 69.9% were male, and the mean (SD) age was 40.66 (13.85) years. Forty-one percent had elevated dysphagia and 46% had elevated hypervigilance and anxiety. Esophageal symptom-specific anxiety emerged as the most important predictor of Brief Esophageal Dysphagia Questionnaire severity (44.8% of the variance), Visual Dysphagia Question of EoE Activity Index severity (26%), and poor health-related quality of life (HRQoL) (55.3%). Hypervigilance was also important, but to a lesser extent. Pathophysiological variables did not significantly predict symptoms or HRQoL. Recent food impaction can predict symptom-specific anxiety and proton pump inhibitor use can reduce hypervigilance.
CONCLUSIONS
Hypervigilance and symptom-specific anxiety are important for our understanding of self-reported patient outcomes in EoE. These processes outweigh endoscopic and histologic markers of EoE disease activity across dysphagia, difficulty eating, and HRQoL. Clinicians should assess hypervigilance and anxiety, especially in patients with refractory symptoms and poor HRQoL.
Identifiants
pubmed: 34153298
pii: S0016-5085(21)03137-1
doi: 10.1053/j.gastro.2021.06.023
pmc: PMC8463417
mid: NIHMS1716838
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133-1144Subventions
Organisme : NIDDK NIH HHS
ID : P01 DK117824
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Aliment Pharmacol Ther. 2018 May;47(9):1270-1277
pubmed: 29528128
Dysphagia. 2021 Apr 8;:
pubmed: 33830347
Aliment Pharmacol Ther. 2011 Oct;34(7):790-8
pubmed: 21806649
Am J Gastroenterol. 2016 Apr;111(4):493-9
pubmed: 26881974
Am J Gastroenterol. 2020 Jun;115(6):853-858
pubmed: 32195733
Gut. 2013 Apr;62(4):489-95
pubmed: 22619364
Neurogastroenterol Motil. 2021 Feb 13;:e14102
pubmed: 33580617
Gastroenterology. 2020 May;158(6):1776-1786
pubmed: 32359562
Dig Dis Sci. 2018 Jul;63(7):1756-1762
pubmed: 29611076
Ann N Y Acad Sci. 2018 Dec;1434(1):84-93
pubmed: 29762879
Dis Esophagus. 2019 Nov 13;32(9):
pubmed: 31329864
Aliment Pharmacol Ther. 2017 Jan;45(2):300-309
pubmed: 27868216
Gastroenterology. 2021 Jan;160(1):47-62
pubmed: 33091411
Dig Dis Sci. 2021 Oct;66(10):3312-3321
pubmed: 33492534
Neurogastroenterol Motil. 2016 Dec;28(12):1854-1860
pubmed: 27380834
Neurogastroenterol Motil. 2021 Aug;33(8):e14081
pubmed: 33432708
United European Gastroenterol J. 2018 Feb;6(1):38-45
pubmed: 29435312
JAMA Psychiatry. 2021 Apr 1;78(4):372-379
pubmed: 33533876
J Clin Gastroenterol. 2011 Oct;45(9):769-74
pubmed: 21552137
Rev Gastroenterol Mex (Engl Ed). 2019 Oct - Dec;84(4):427-433
pubmed: 30292584
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101672
pubmed: 33722776
Gastroenterology. 2014 Dec;147(6):1255-66.e21
pubmed: 25160980
Gastrointest Endosc Clin N Am. 2018 Jan;28(1):35-45
pubmed: 29129298
Gastroenterol Hepatol. 2018 Apr;41(4):281-291
pubmed: 29422238
J Asthma Allergy. 2019 Dec 09;12:389-399
pubmed: 31849499
Am J Gastroenterol. 2020 Mar;115(3):367-375
pubmed: 31990697
Gastroenterology. 2011 Jan;140(1):82-90
pubmed: 20858491
JMIR Ment Health. 2020 Jun 24;7(6):e16525
pubmed: 32579127
Aliment Pharmacol Ther. 2019 May;49(9):1116-1125
pubmed: 30887555
Dis Esophagus. 2018 Apr 1;31(4):
pubmed: 29088336
Aliment Pharmacol Ther. 2015 Oct;42(8):1000-10
pubmed: 26271642
Gastroenterology. 2016 Mar;150(3):581-590.e4
pubmed: 26584601
Neurogastroenterol Motil. 2015 Mar;27(3):313-23
pubmed: 25428520
Clin Gastroenterol Hepatol. 2021 Jan 13;:
pubmed: 33348046
Am J Gastroenterol. 2018 Mar;113(3):348-357
pubmed: 29336433
Neurogastroenterol Motil. 2021 Apr;33(4):e14025
pubmed: 33169488
Adv Ther. 2020 Oct;37(10):4458-4478
pubmed: 32880822
Rev Esp Enferm Dig. 2014 Jun;106(6):386-94
pubmed: 25361449
Inflamm Intest Dis. 2018 Mar;2(3):163-170
pubmed: 30018966